



APPENDIX A

"MARKED UP" PARAGRAPHS ILLUSTRATING THE AMENDMENTS MADE TO THE  
SPECIFICATION OF 09/775,856 WITH ENTRY OF THIS AMENDMENT

ABSTRACT OF THE DISCLOSURE

The application relates to the purification and characterization of a family of A-type inositolphosphoglycans (IPGs) from human liver and placenta. These substances are shown to have the biological activity associated with A-type IPG fractions, namely regulating lipogenic activity and inhibiting cAMP dependent protein kinase. The characterization of the compounds demonstrates that they contain metal ions, in particular  $Zn^{2+}$ , and optionally phosphate. The compounds and their antagonists have uses as pharmaceuticals, e.g. for the treatment of diabetes, and in screening for synthetic analogs.

09/775,856